Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, New York, USA.
J Infect Dis. 2011 Sep 15;204(6):832-6. doi: 10.1093/infdis/jir424.
CXCL9 (monokine induced by IFN γ [Mig]) and CXCL10 (interferon [IFN] γ-inducible protein 10 [IP-10]) have been associated with hepatic fibrosis in predominantly white hepatitis C virus (HCV)-infected patients. We investigated their potential as noninvasive markers of hepatic fibrosis and fibrosis progression in African-American patients. Peripheral chemokine levels were measured in 115 HCV-infected patients within 4 months of liver biopsy; patients underwent a second biopsy after 3-5 years. CXCL10 levels appeared to be higher in patients with advanced fibrosis on the contemporaneous biopsy and were significantly higher in patients with advanced fibrosis compared with those with minimal fibrosis on the later biopsy (P = .0045). Therefore, CXCL10 has potential as a marker of fibrosis progression in African-American HCV-infected patients.
趋化因子 CXCL9（IFNγ 诱导的单核细胞因子[Mig]）和 CXCL10（IFNγ 诱导蛋白 10[IP-10]）与白人丙型肝炎病毒（HCV）感染患者的肝纤维化有关。我们研究了它们在非裔美国 HCV 感染患者中作为非侵入性肝纤维化和纤维化进展标志物的潜力。在肝活检后 4 个月内对 115 名 HCV 感染患者进行了外周趋化因子水平检测；3-5 年后，患者进行了第二次活检。在同期活检中，CXCL10 水平在纤维化程度较高的患者中似乎更高，与后来活检中纤维化程度最低的患者相比，纤维化程度较高的患者 CXCL10 水平显著更高（P=0.0045）。因此，CXCL10 有可能成为非裔美国 HCV 感染患者纤维化进展的标志物。
